YouTubeFacebookLinkedInTwitterinstagramrss

Solentim to supply cell line development solutions for Samsung Biologics’ new R&D center in San Francisco



BOURNEMOUTH, UNITED KINGDOM - Oct 7, 2020 - Solentim is pleased to announce the adoption of its VIPS™ single cell seeding platform and Cell Metric® CLD into Samsung Biologics’ new research and development facility in San Francisco, CA. These instruments are designed for single cell cloning and assurance of monoclonality to increase the speed and efficiency of Master Cell Bank development.

Samsung’s new R&D facility in San Francisco will offer rapid, high quality development services, including cell line development, to its global customers. Solentim’s VIPS and Cell Metric CLD instruments will be used in conjunction with Samsung Biologics’ recently launched proprietary cell line platform, S-CHOice™, announced last month.

Dr Mark Truesdale, CEO of Solentim, said, “We’re pleased to extend our long-standing partnership with Samsung Biologics, which has previously purchased and enjoyed success with our equipment in its headquarter operations.”

ENDS

For further information, contact:

Corporate Contacts:
Solentim Ltd

Ian Taylor, CBO
T: +44 (0)1202 051813
E: ian.taylor@solentim.com

PR Contact:
Sciad Communications Ltd

Emma Pickup/Richard Anderson
T: +44 (0)20 3405 7892
E: solentim@sciad.com

Notes to Editors

About Solentim
Solentim is the trusted global leader for solutions to create, isolate, and characterize the highest value cells for the development of new biological medicines, including cell and gene therapies, monoclonal antibodies, vaccines and stem cells. For our customers, which include most of the world’s leading pharmaceutical and biotherapeutics companies, we are the partner of choice for facilitating the highest level of assurance in cell line development for therapeutic protein and viral vector production.  

Our portfolio of proven and innovative instruments (including VIPS™, Cell Metric® and Cell Metric® CLD) are designed for single cell cloning and assurance of monoclonality. Combined with enabling reagents (including InstiGRO™ and Leap-In Transposase®) from our partners, and our unparalleled domain expertise, we transform the speed and efficiency of clonally-derived Master Cell Bank development. Our customers trust in our technology to ensure they are confidently prepared for regulatory review. 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1